ArticleEuropean child & adolescent psychiatry2026
Drug utilisation of antipsychotics and lithium in Sweden 2008-2021 - a nationwide study of children aged 5-17 years.
Article in European child & adolescent psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antipsychotics are mainly used for severe psychiatric disorders. Risperidone is the only antipsychotic approved for younger children. Aripiprazole is approved for older children, ziprasidone and lurasidone for adolescents. To describe paediatric utilisation of antipsychotic drugs in Sweden. Dispensations of antipsychotic drugs to children aged 5-17 years from 2008 to 2021 were analysed using the National Prescribed Drug Register and recorded diagnoses were obtained from the National Patient Register. Overall, dispensations of antipsychotics to children increased from 16.7 to 36.9/10,000 between 2008 and 2021. The increase was larger in girls, from 12.3 to 36.6/10,000. New users of antipsychotics increased by 121% in the same period, from 7.9 to 17.5/10.000. In 2019, in children aged 12-17, 63% of girls and 71% of boys were dispensed had at least three dispensations of antipsychotics, while the corresponding proportion in children aged 5-11 were 52% for girls and 63% for boys. Risperidone was the most common drug in boys of all ages and in girls aged 5-11. In girls aged 12-17, aripiprazole and quetiapine were most common. The proportion of on-label antipsychotic use was 21% in girls and 15% in boys based in authorised product information and increased to 37% and 45%, respectively, when aligning with national guidelines. The use of antipsychotics has increased, with the proportion of girls starting treatment at the end of study period exceeding that of boys. A considerable proportion of prescriptions was off-label, even when considering national guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.